695 related articles for article (PubMed ID: 19501212)
1. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial.
Plewig G; Cunliffe WJ; Binder N; Höschen K
Contraception; 2009 Jul; 80(1):25-33. PubMed ID: 19501212
[TBL] [Abstract][Full Text] [Related]
2. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon).
Worret I; Arp W; Zahradnik HP; Andreas JO; Binder N
Dermatology; 2001; 203(1):38-44. PubMed ID: 11549798
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen.
Brucker C; Hedon B; The HS; Höschen K; Binder N; Christoph A
Contraception; 2010 Jun; 81(6):501-9. PubMed ID: 20472117
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate.
Palombo-Kinne E; Schellschmidt I; Schumacher U; Gräser T
Contraception; 2009 Apr; 79(4):282-9. PubMed ID: 19272497
[TBL] [Abstract][Full Text] [Related]
5. Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations.
Lello S; Primavera G; Colonna L; Vittori G; Guardianelli F; Sorge R; Raskovic D
Gynecol Endocrinol; 2008 Dec; 24(12):718-23. PubMed ID: 19172543
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment.
Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
J Drugs Dermatol; 2009 Sep; 8(9):837-44. PubMed ID: 19746676
[TBL] [Abstract][Full Text] [Related]
7. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial.
Redmond GP; Olson WH; Lippman JS; Kafrissen ME; Jones TM; Jorizzo JL
Obstet Gynecol; 1997 Apr; 89(4):615-22. PubMed ID: 9083323
[TBL] [Abstract][Full Text] [Related]
8. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study.
Schramm G; Heckes B
Contraception; 2007 Aug; 76(2):84-90. PubMed ID: 17656175
[TBL] [Abstract][Full Text] [Related]
9. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
van Vloten WA; van Haselen CW; van Zuuren EJ; Gerlinger C; Heithecker R
Cutis; 2002 Apr; 69(4 Suppl):2-15. PubMed ID: 12096825
[TBL] [Abstract][Full Text] [Related]
10. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study.
Anthuber S; Schramm GA; Heskamp ML
Clin Drug Investig; 2010; 30(4):211-20. PubMed ID: 20225905
[TBL] [Abstract][Full Text] [Related]
11. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
Koltun W; Lucky AW; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of efficacy, safety and effects on symptoms of androgenization of a generic oral contraceptive containing chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg.
Hadji P; Biskup J; Boekhoff J; Ziller M; Bonn M; Rovati L
Contraception; 2012 Oct; 86(4):359-65. PubMed ID: 22445436
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate.
Vartiainen M; de Gezelle H; Broekmeulen CJ
Eur J Contracept Reprod Health Care; 2001 Mar; 6(1):46-53. PubMed ID: 11334476
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
Lucky AW; Henderson TA; Olson WH; Robisch DM; Lebwohl M; Swinyer LJ
J Am Acad Dermatol; 1997 Nov; 37(5 Pt 1):746-54. PubMed ID: 9366821
[TBL] [Abstract][Full Text] [Related]
16. [The effectiveness of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type].
Gollnick H; Albring M; Brill K
Ann Endocrinol (Paris); 1999 Sep; 60(3):157-66. PubMed ID: 10520404
[TBL] [Abstract][Full Text] [Related]
17. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome.
Uras R; Orrù M; Pani F; Marotto MF; Pilloni M; Guerriero S; Etzi R; Zedda P; Sorge R; Lello S; Melis GB; Paoletti AM
Contraception; 2010 Aug; 82(2):131-8. PubMed ID: 20654753
[TBL] [Abstract][Full Text] [Related]
18. A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment.
Lucky AW; Koltun W; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
Cutis; 2008 Aug; 82(2):143-50. PubMed ID: 18792547
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)--an open-label, prospective, noncontrolled, office-based Phase III study.
Zahradnik HP; Hanjalic-Beck A
Contraception; 2008 May; 77(5):337-43. PubMed ID: 18402849
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the new antiandrogenic oral contraceptive Belara.
Zahradnik HP; Goldberg J; Andreas JO
Contraception; 1998 Feb; 57(2):103-9. PubMed ID: 9589837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
